NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)

NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)

Author: National Tuberculosis Controllers Association (NTCA)
Publication Date: 2018
Country of Origin: United States
Format: Brochures
Language: English

Abstract

The resource was designed to help healthcare providers:
1. Quickly identify and answer key questions when considering whether to start a patient on the isoniazid-rifapentine (3HP) regimen
2. Assess the appropriateness of self-administered therapy of 3HP for each individual patient
3. Ensure that the correct drugs for the 3HP regimen are prescribed and provided to the patient
4. Handle questions on side effects and adverse reactions for a patient currently on the 3HP regimen

Publisher:

National Tuberculosis Controllers Association

Audience(s):

Health Professionals, Physicians

Topic:

Diagnosis, TB Treatment, Treatment- Latent TB Infection, Treatment- Medication Information

Notes:

The material supplements CDC's guidance, Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection, MMWR, June 29, 2018;67(25):723–726.

Disclaimer: The information on the Find TB Resources Website is made available as a public service. Neither the Centers for Disease Control and Prevention nor the National Prevention Information Network endorses the organizations, Website s, and materials presented. It is the responsibility of the user to evaluate this information prior to use based on individual, community, and organizational needs and standards.